You are here

Article Text

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-943-ESGO The significance of lower uterine segment involvement in endometrial cancer
Free
  1. Sharon Davidesko1,
  2. Mihai Meirovitz2,
  3. Hagar Brami1,
  4. Ruthy Shaco-Levy3,
  5. Amit Meir2,
  6. Alexander Rabinovich2,
  7. Yarden Kezerle3,
  8. Samueli Benzion3,
  9. Shaked Yarza4 and
  10. Roy Kessous2
  1. 1Department of Gynecology B, Soroka University Medical Center, Beer Sheva, Israel
  2. 2Department of Gynecologic Oncology, Soroka University Medical Center, Beer Sheva, Israel
  3. 3Department of Pathology, Soroka University Medical Center, Beer Sheva, Israel
  4. 4Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel

Abstract

Introduction/Background Limited data suggests that lower uterine segment (LUS) involvement may be associated with other poor prognostic factors such as lymphovascular space involvement (LVSI), deep myometrial invasion and high-grade histology, but its impact on disease progression is unclear. This study assesses the impact of LUS involvement on the prognosis of women with endometrial cancer.

Methodology A revision of all pathological samples following surgical staging for endometrial cancer between the years 2002 to 2022 was performed and retrospective clinical data collected from patients’ medical records. Characteristics of women with and without LUS involvement were compared and outcomes of both groups analysed. Kaplan Meyer survival curves were constructed comparing overall survival (OS) and progression-free survival (PFS) in both groups.

Abstract 2022-RA-943-ESGO Figure 1
Abstract 2022-RA-943-ESGO Figure 1

Kaplan meyer survival curves for 5 year survival (left) and recurrence (right) comparing cases with and without lower uterine segment involvement

Results 429 women were included in the study, 45 (10.5%) were diagnosed with LUS involvement. No differences were found between the groups regarding the demographic or clinical characteristics including age, hypertension, diabetes mellitus, smoking, obesity, infertility, hormonal therapy or histological subtype. LUS involvement was significantly associated with LVSI (40% vs. 22% p=0.01), higher stage at diagnosis (p=0.04), and shorter PFS (30.0 months vs. 55.2 months, p=0.02). A decrease in 5 year OS was also observed although this marginally missed statistical significance (88% vs. 77%, p=0.06). A trend towards decreased PFS and OS was demonstrated in the Kaplan Meyer survival curves, however these failed to reach statistical significance, possibly due to an insufficient number of cases (figure 1).

Conclusion LUS involvement appears to confer a poorer prognosis with decreased PFS and a trend towards decreased OS and may be an additional factor to consider in decisions regarding adjuvant treatment following surgical staging for endometrial cancer.

https://doi.org/10.1136/ijgc-2022-ESGO.261

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.